Attorneys have characterized the recent U.S. Supreme Court decision in Bristol-Myers Squibb v. Superior Court of California as game-changing for mass tort programs in state court, but lawyers for more than 90 plaintiffs suing Johnson & Johnson over its pelvic mesh products have said in court papers the ruling should not affect the mass tort program pending in Philadelphia.

Lead attorneys in the mass tort program filed their response Sept. 7 to J&J’s recent bid to get most cases pending against it in Pennsylvania removed from Philadelphia Court of Common Pleas.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]